High-dose chemotherapy with autologous stem cell support in patients with breast cancer.

[1]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Heimfeld,et al.  A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. , 1997, Blood.

[3]  G. Hortobagyi,et al.  Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. , 1997, Seminars in oncology.

[4]  E. Shpall,et al.  Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. , 1997, Experimental hematology.

[5]  G. Hortobagyi,et al.  Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Yen,et al.  High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Falkenburg,et al.  The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis , 1997, Annals of Hematology.

[8]  D. Wickerham,et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Armitage,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Hainsworth,et al.  Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses , 1997, Bone Marrow Transplantation.

[11]  L. Norton,et al.  HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. , 1997, Oncology.

[12]  P. Richardson,et al.  Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Kanz,et al.  Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. , 1996, Blood.

[14]  R. Champlin,et al.  Purging: the separation of normal from malignant cells for autologous transplantation , 1996, Transfusion.

[15]  B. Samuels,et al.  Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  K. Weinberg,et al.  Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. , 1996, Blood.

[17]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Holyoake,et al.  Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. , 1996, Blood.

[19]  J. Wingard,et al.  Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Nienhuis.  Gene transfer into hematopoietic cells. , 1996, Hematology and cell therapy.

[21]  W. Anderson,et al.  High-Dose Chemotherapy and Autologous Bone Marrow Plus Peripheral Blood Stem Cell Transplantation for Patients with Lymphoma or Metastatic Breast Cancer: Use of Marker Genes to Investigate Hematopoietic Reconstitution in Adults. University of Southern California, Norris Cancer Center, Los Angeles, C , 1996 .

[22]  J G Bender,et al.  Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. , 1996, Blood.

[23]  R. Champlin.  Purging: elimination of malignant cells from autologous blood or marrow transplants , 1996, Current opinion in oncology.

[24]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[25]  L. Moscinski,et al.  High Dose versus Standard Dose Chemotherapy for the Treatment of Breast Cancer , 1995, Annals of the New York Academy of Sciences.

[26]  L. Tuason,et al.  High‐Dose Busulfan and Cyclophosphamide Followed by Autologous Bone Marrow Transplantation and/or Peripheral Blood Progenitor Cell Rescue for Metastatic Breast Cancer , 1995, American journal of clinical oncology.

[27]  S. Hegewisch-Becker,et al.  Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. , 1995, Gene therapy.

[28]  Purdy Mh.  Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. , 1995 .

[29]  J. Sosman,et al.  High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  A. Parreira,et al.  Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. , 1995, Experimental hematology.

[31]  M. Gottesman,et al.  Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. , 1995, Gene therapy.

[32]  C. Hudis,et al.  Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  L. Seymour,et al.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Fairclough,et al.  Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  N. Mulder,et al.  Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. , 1995, Anticancer research.

[36]  T. Spitzer,et al.  Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. , 1995, Bone marrow transplantation.

[37]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[38]  L. Morris,et al.  Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire. , 1995, Transplantation proceedings.

[39]  G. Rosner,et al.  The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local‐regional radiotherapy for breast cancer , 1994, Cancer.

[40]  A. Bernad,et al.  Accelerated and long-term hematopoietic engraftment in mice transplanted with ex vivo expanded bone marrow. , 1994, Bone marrow transplantation.

[41]  L. Norton,et al.  Optimization of Conditions for Ex Vivo Expansion of CD34' Cells From Patients With Stage IV Breast Cancer , 1994 .

[42]  J. Vredenburgh,et al.  The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. , 1994, Seminars in oncology.

[43]  W. Wilson,et al.  Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. , 1994, Human gene therapy.

[44]  R. Andrews,et al.  Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. , 1994, Blood.

[45]  S. Heimfeld,et al.  Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. , 1994, Blood.

[46]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[47]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[48]  N. Davidson,et al.  Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. , 1994, Cancer research.

[49]  A. Nienhuis,et al.  Gene Transfer into Hematopoietic Cells: Implications for Cancer Therapy , 1994, Annals of the New York Academy of Sciences.

[50]  A. Bernad,et al.  Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene‐transfer to murine lympho‐haemopoietic stem cells , 1994, British journal of haematology.

[51]  G. Hortobagyi,et al.  Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.

[52]  R. Mick,et al.  High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. , 1994, Bone marrow transplantation.

[53]  J. Doroshow,et al.  High‐dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high‐risk primary breast cancer , 1994, Cancer.

[54]  A. Deisseroth,et al.  Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. , 1994, Cancer gene therapy.

[55]  N. Davidson,et al.  Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Hudis,et al.  Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. Beveridge,et al.  Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Mick,et al.  High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Eddy.  High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  L. Norton,et al.  Metastatic breast cancer. Length and quality of life. , 1991, The New England journal of medicine.

[62]  R. Bast,et al.  Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4‐hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres , 1991, Cancer.

[63]  R. Beveridge,et al.  High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[64]  G. Hortobagyi,et al.  A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  D. Young,et al.  Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. , 1990 .

[66]  R. Livingston,et al.  Combination chemotherapy and high‐dose cyclophosphamide intensification for poor prognosis breast cancer. A southwest oncology group study , 1989, Cancer.

[67]  N. S. Mcnutt,et al.  B-cell lymphoma. , 1989, The Journal of dermatologic surgery and oncology.

[68]  I. Tannock,et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  T. Shea,et al.  High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G. Hortobagyi,et al.  Multivariate analysis of prognostic factors in metastatic breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  G. Hortobagyi,et al.  Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens , 1981, Cancer.

[74]  G. Hortobagyi,et al.  Complete remissions in metastatic breast cancer treated with combination drug therapy. , 1979, Annals of internal medicine.

[75]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.

[76]  E. Shpall,et al.  Peripheral blood stem cell harvesting and CD34-positive cell selection. , 1997, Cancer treatment and research.

[77]  P. Goss,et al.  Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. , 1996, Journal of Clinical Oncology.

[78]  Peters Wp.  High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes. , 1995 .

[79]  M. Moore,et al.  Ex vivo expansion of CD34+ hematopoietic progenitors. , 1994, Progress in clinical and biological research.

[80]  S. Hancock,et al.  Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice , 1994, Stem cells.

[81]  J. Doroshow,et al.  High‐dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high‐risk primary breast cancer , 1994, Cancer.

[82]  E. Shpall,et al.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  B. Edwards,et al.  High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. , 1994, Bone marrow transplantation.

[84]  W. Velasquez,et al.  Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer. , 1993, Journal of hematotherapy.

[85]  J. Gribben,et al.  The immunological treatment of human marrow in vitro in transplantation biology. , 1993, Cancer treatment and research.

[86]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  G. Rosner,et al.  4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  L. Seymour,et al.  First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. , 1989, Oncology.

[89]  Hryniuk Wm.  The importance of dose intensity in the outcome of chemotherapy. , 1988 .

[90]  B. Teicher,et al.  Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. , 1988, Cancer research.

[91]  M. Levine,et al.  Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.